Different exposure duration of adjuvant icotinib in stage II-IIIA non-small cell lung cancer patients with positive EGFR mutation (ICOMPARE study): A randomized, open-label phase 2 study.

Chao Lyu,Rui Wang,Shaolei Li,Shi Yan,Yuzhao Wang,Jinfeng Chen,Liang Wang,Yinan Liu,Zhanlin Guo,Jia Wang,Yuquan Pei,Lei Yu,Nan Wu,Jun Chen,Yanheng Liu,Shanqing Li,Bing Han,Lieming Ding,Li Mao,Yue Yang

Different exposure duration of adjuvant icotinib in stage II-IIIA non-small cell lung cancer patients with positive EGFR mutation (ICOMPARE study): A randomized, open-label phase 2 study.

2021

Chao Lyu
Rui Wang
Shaolei Li
Shi Yan
Yuzhao Wang
Jinfeng Chen
Liang Wang
Yinan Liu
Zhanlin Guo
Jia Wang
Yuquan Pei
Lei Yu
Nan Wu
Jun Chen
Yanheng Liu
Shanqing Li
Bing Han
Lieming Ding
Li Mao
Yue Yang

8521Background: EGFR-TKI has been widely used in the treatment for advanced non-small cell lung cancer (NSCLC). Previous studies, such as the EVIDENCE study and the ADAURA study, have confirmed tha...

Keywords:

stage ii
Medicine
Lung cancer
non small cell
Icotinib
Internal medicine
Phases of clinical research
Oncology
Adjuvant
egfr mutation
exposure duration

Correction
Source
Cite
Save
Machine Reading By IdeaReader

References

Citations